South Korea, US Discuss Chip Investments Amid Tariff Plans 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Add as a preferred source on Google
SAN DIEGO, Feb. 21, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2017 financial and operating results after the close of U.S. financial markets on Wednesday, February 28, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2018 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 1894785 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
[email protected]
Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]
